Porphyria cutanea tarda

Seminars in Liver Disease

Volumn 18, Issue 1, 1998, Pages 67-75

  Elder, George H ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Mutations; Pathogenesis; Uroporphyria; Uroporphyrinogen decarboxylase

Indexed keywords

CHLOROQUINE; UROPORPHYRINOGEN DECARBOXYLASE;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; ENZYME ACTIVITY; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; HUMAN; LIVER CELL DAMAGE; MOLECULAR GENETICS; PENETRANCE; PORPHYRIA CUTANEA TARDA; PREVALENCE; PRIORITY JOURNAL; SKIN DISEASE;

EID: 0031892668     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007142     Document Type: Article

References (92)

1. Harber LC, Bickers DR. In: Photosensitivity diseases: principles of diagnosis and treatment. Philadelphia, Saunders, 1981, pp 189-223.
2. Martasek P, Kordak V, Zonbek V, et al. Epidemiology of porphyria cutanea tarda in Czechoslovakia and Mongolia. Bolletino dell'Instituto Dermatologica S Gallicano 1987;8:330-331.
3. Kushner JP, Barbuto AJ, Lee GR. An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J Clin Invest 1976;58:1089-1097
4. De Verneuil H, Aitken G, Nordmann Y. Familial and sporadic porphyria cutanea: two different diseases. Hum Genet 1978; 44:145-151
5. Elder GH, Urquhart AJ, De Salamanca R et al. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet 1985;1:229-232
6. Elder GH, Roberts AG, De Salamanca RE. Genetics and pathogenesis of human uroporphyrinogen decarboxylase defects Clin Biochem 1989;22:163-168
7. McManus J, Blake D, Ratnaike S. An assay of uroporphyrinogen decarboxylase in erythrocytes. Clin Chem 1988;34:2355-2357
8. Roberts AG, Elder GH, Newcombe RG, et al. Heterogeneity of familial porphyria cutanea tarda. Med Genet 1988;25:669-676
9. Held JL, Sassa S, Kappas A et al. Erythrocyte uroporphyrinogen decarboxylase activity in porphyria cutanea tarda. a study of 40 consecutive patients. J Invest Dermatol 1989;93:332-334
10. Koszo F, Morvay M, Dobozy A, Simon N. Erythrocyte uroporphyrinogen decarboxylase activity in 80 unrelated patients with porphyria cutanea tarda. Brit J Dermatol 1992;126:446-449
11. Roberts AG, Elder GH, De Salamanca RE, Mascaro JM. A mutation (G281E) of the human oroporphyrinogen decarboxylase gene causes both hepatoerythropoietic porphyria and overt familial porphyria cutanea tarda. J Invest Dermatol 1995;104:500-502
12. Elder GH, Roberts AG. Uroporphyrinogen decarboxylase. J Bioenerg Biomembr 1994;27:207-214
13. Garey JR, Franklin KF, Brown AD, et al Analysis of uroporphyrinogen decarboxylase complementary DNAs in sporadic porphyria cutanea tarda. Gastroenterology 1993;105:165-169
14. D'Alessandro Gandolfo L, Griso D, Mari A, et al. Familial porphyria cutanea tarda with normal erythrocytic urodecarboxylase an exception to the rule Dermatologica 1989;178:206
15. Garey JR, Hansen JL, Harrison LM, Kennedy JB, Kushner JP A point mutation in the coding region of uroporphyrinogen decarboxylase associated with familial porphyria cutanea tarda. Blood 1989;73:892-895
16. McManus JF, Begley CG, Sassa S, Ratnaike S. Five new mutations in the uroporphyrinogen decarboxylase gene identified in families with cutaneous porphyria. Blood 1996;88:3586-3600
17. Sorkin L, Mendez M, Rossetti MV, et al. Identification of six new mutations in the uroporphyrinogen decarboxylase gene Am J Hum Genet 1996;59:A285
18. Moran-Jimenez MJ, Ged C, Romana M, et al. Uroporphyrinogen decarboxylase: complete gene sequence and molecular study of three families with hepatoerythropoietic porphyria. Am J Hum Genet 1996;58:712-721
19. Meguro K, Fujita H, Ishida N, et al. Molecular defects of uroporphyrinogen decarboxylase in a patient with mild hepatoerythropoietic porphyria. J Invest Dermatol 1994;102:681-685
20. Sweeney GD. Porphyria cutanea tarda, or the uroporphyrinogen decarboxylase deficiency diseases. Clin Biochem 1986;19:3-14
21. Cripps DJ, Peters HA, Gocman A, et al. Porphyria turcica due to hexachlorobenzene - a 20 to 30 year follow-up study on 204 patients. Brit J Dermatol 1984;111:413-422
22. Altomare G, Capella GL. Occupational porphyria cutanea tarda due to exposure to symmetrical triazine herbicides Eur J Dermatol 1995;5:66-68
23. Grossman ME, Bickers DR, Poh-Fitzpatrick MB, et al. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients Amer J Med 1979;67:277
24. Mascaro JM, Herrero C, Lecha M, et al. Uroporphyrinogen decarboxylase deficiencies porphyria cutanea tarda and related conditions. Sem Dermatol 1986;5:115-124
25. Sierseema PD, Rademakers LHP, Cleton MI, et al. The difference in liver pathology between sporadic and familial forms of porphyria cutanea tarda - the role of iron. J Hepatol 1995;23: 259-267
26. Bickers DR, Pathak MA. The porphyrtas. In: Fitzpatrick TB, Eisen AZ, Wolff K et al (eds): Dermatology in general medicine. 4th ed. New York, McGraw-Hill, 1995, pp 1854-1893
27. O'Reilly K, Snape J, Moore MR. Porphyria cutanea tarda resulting from primary hepatocellular carcinoma. Clin Exp Dermatol 1988;13:44-48
28. Poh-Fitzpatrick MB, Porphyria, pseudopophyria, pseudo-pseudoporphyria . . . ? Arch Dermatol 1986;122:403-404
29. Poh-Fitzpatrick MB, Sosin AE, Bemis J. Porphyrin levels in plasma and erythrocytes of chronic hemodialysis patients. J Am Acad Dermatol 1982;7:100-104
30. Liu AC. Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognised porphyria cutanea tarda. West J Med 1995;162:548-551
31. Kushner JP, Steinmuller P, Lee GR. The role of iron in the pathogenesis of porphyria cutanea tarda J Clin Invest 1975;56:661-667
32. Levin EY. Enzymatic properties of uroporphyrinogen III cosynthetase. Biochemistry 1971;10:4669-4675
33. Seubert S, Seubert A, Rumpf KW, Kiffe H. A porphyria cutanea tarda-like distribution pattern of porphyrins in plasma, hemodialysate, hemofiltrate and urine of patients on chronic hemodialysis. J Invest Dermatol 1985;85:107-109
34. Elder GH, Smith SG, Smyth SJ. Laboratory investigation of the porphyrias Ann Clin Biochem 1990;27:395-412
35. Poh-Fitzpatrick MB. A plasma porphyrin fluorescene marker for variegate porphyria. Arch Dermatol 1980;116:543-547
36. Elder GH. Porphyria cutanea tarda: a multifactorial disease. Rec Adv Dermatol 1990;8:55-69
37. Lopez-Miras A, De Salamanca RE, Garcia-Perez A, et al. Porphyria cutanea tarda as seen in Madrid. Bolletino dell'Instituto Dermatologico S. Gallicano 1987;8:335-336
38. Fargion S, Fracanzani AL, Romano R. et al. Genetic hemochromatosis in Italian patients with porphyria cutanea tarda: possible explanation for iron overload J Hepatol 1996;24:564-569
39. Herrero C, Vicente A, Bruguera M, et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993;341: 788-789
40. Stolzel U, Kostler E, Koszka C, et al. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany. Hepatology 1995;21:1500-1503
41. Cortes JM, Oliva H, Paradinas FJ, Fernandes-Guio C. The pathology of the liver in porphyria cutanea tarda. Histopathology 1980;4:471-485
42. Bruguera M. Liver involvement in porphyria. Sem Dermatol 1986;5:178-185
43. Dehlin O, Enerback L, Lundvall O. Porphyria cutanea tarda: a genetic disease? Acta Med Scand 1973;194:265-270
44. Doss M, Look D, Henning H, et al. Hepatic porphyrins and urinary porphyrins and porphyrin precursors in liver cirrhosis. Klin Wochenshr 1972;50:1025-1032
45. Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. In: Scriver CR, Beaude AL, Sly WS, Valle D (eds): The molecular and metabolic basis of inherited disease 7th ed. New York, McGraw-Hill, 1995, pp 2103-2160
46. Fargion S, Piperno A, Cappellini MD, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992;16:1322-1326
47. Ferri C, Baicchi U, Civita La L, et al. Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda. Eur J Clin Invest 1993;23:851-855
48. Navas S, Bosch O, Castillo I, et al. Porphyria cutanea tarda and Hepatitis C virus and B viruses infection: a retrospective study. Hepatology 1995;21:279-284
49. Quecedo L, Costa J, De Salamanca RE. The role of the hepatitis C virus in the liver disease of porphyria cutanea tarda. Medicina Clinica 1996;106:321-324
50. Lacour JP, Bodokh I, Castanet J, Bekri S, et al. Porphyria cutanea tarda and antibodies to hepatitis C virus. Br J Dermatol 1993;128:121-123
51. Cribier B, Petiau P, Keller F, et al. Porphyria cutanea tarda and hepatitis C viral infection. Arch Dermatol 1995;131:801-804
52. Bonkovsky HL, Poh-Fitzpatrick M, Tattrie C, DiBisceglie A. Porphyria cutanea tarda and hepatitis C in the USA Hepatology 1996;24:1440
53. Sawicki M Parera V, Mendez M, et al. Prevalence of hepatitis C viral infection in patients suffering from porpjhyria cutanea tarda in Argentina. Hepatology 1976;23:I-94
54. Gibson PR, Ratnaike S, Blake D, Sinickas V. Porphyria cutanea tarda and hepatitis C. Med J Aust 1995;162:54
55. Malina L, Arenberger P, Kracikova J. Frekvence virove hepatitidy C u nemocnych pozdni kozni porfyrii (PCT). Cas Lek Cesk 1994;133:599-601
56. Siersema PD, ten Kate FJW, Mulder PGH, Wilson JHP. Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver 1992;12:56-61
57. Murphy A, Dooley S, Hillary IB, Murphy GM. HCV infection in porphyria cutanea tarda. Lancet 1993;341:1534-1535
58. O'Connor W, Murphy GM, Darby C, et al. Abnormal porphyrin metabolism in HIV infection. Brit J Dermatol 1994;131 (suppl 44):37
59. Nomura N, Zolla-Pazner S, Simberkoff M, et al. Abnormal serum porphyrin levels in patients with the acquired immunodeficiency syndrome with or without hepatitis C virus infection. Arch Dermatol. 1996;132:906-910
60. Coburn PR, Coleman JC, Cream JJ, et al. Porphyria cutanea tarda and porphyria variegata unmasked by viral hepatitis. Clin Exp Dermatol 1985;10:169-173
61. Castanet J, Lacour JP, Bodokh I, et al. Porphyria cutanea tarda in association with human immunodeficiency virus infection: is it related to hepatitis C virus infection? Arch Dermatol 1994;130: 664-665
62. Bengtsson NO, Hardell L, Porphyrias, porphyrins and hepatocellular cancer. Br J Cancer 1986;54:115-117
63. Fakan F, Chlumska A. Demonstration of needle-shaped hepatic inclusions in porphyria cutanea tarda using the ferric ferricyanide reduction test. Virchows Archiv A 1987;411:365-368
64. Smith AG, Carthew P, Clothier B, et al. Synergy of iron in the toxicity and carcinogenicity of polychlorinated biphenyls (PCBs) and related chemicals. Toxicol Lett 1995;82:945-950
65. Lundvall O, Weinfeld A, Lundin P. Iron storage in porphyria cutanea tarda. Acta Medica Scandinavica 1970;188:37-53
66. Edwards CQ, Griffen LM, Goldgar DE, et al. HLA-Linked hemochromatosis alleles in sporadic porphyria cutanea tarda. Gastroenterology 1989;97:972-981
67. Rocchi E, Gibertini P, Cassanelli M, et al. Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. J Lab Clin Med 1986;107:36-42
68. Adams PC, Powell LW Porphyria cutanea tarda and HLA-linked hemochromatosis - all in the family? Gastroenterology 1987;92:2033-2035
69. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class 1-like gene is mutated in patients with hereditary haemochromatosis. Nature Genet 1996;13:399-408
70. Roberts AG, Whatley SD, Morgan RR, et al. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997;349:321-323
71. Rocci E, Gibertini P, Cassanelli M, et al. Iron removal therapy in porphyria cutanea tarda: phlebotomy versus slow subcutaneous desferrioxamine infusion. Brit J Dermatol 1986;114:621-629
72. Ashton RE, Hawk JLM, Magnus IA. Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. Brit J Dermatol 1981;111:609-613
73. Sarkell B, Patterson JW. Treatment of porphyria cutanea tarda of end-stage renal disease with erythropoietic. J Am Acad Dermatol 1993;29:499-500
74. Kordac V, Jirsa M, Kotal P, et al. Agents affecting porphyrin formation and secretion: implications for porphyria cutanea tarda. Semin Hematol 1989;26:16-23
75. Chlumska A, Chlumsky J, Malina L. Liver changes in porphyria cutanea tarda patients treated with chloroquine. Brit J Dermatol 1980;102:261-266
76. Felsher BF, Carpio NM, Engleking DW, Nunn AT. Decreased hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda. N Eng J Med 1982;306:766-769
77. Visser O, Van den Berg JWO, Edixhoven-Bosdijk A, et al. Development of hexachlorobenzene porphyria in rats' time sequence and relationship with lipid peroxidation. Fd Chem Toxic 1989;27:317-321
78. Bonkovsky HL. Mechanism of iron potentiation of hepatic uroporphyria: studies in cultured chick embryo liver cells. Hepatology 1989;10:354-364
79. Smith AG, Francis JE. Genetic variation of iron-induced uroporphyria in mice. Biochem J 1993;29:29-35
80. De Verneuil H, Sassa S, Kappas A. Purification and properties of uroporphyrinogen decarboxylase from human erythrocytes. J Biol Chem 1983;258:245-246
81. De Matteis F. Drug-induced abnormalities of liver heme biosynthesis. In: Meeks RG, Harrison SD, Bull RJ, Eds: Hepatotoxicology. Boston, CRC Press, 1991, pp 437-479
82. Francis JE, Smith AG. Oxidation of uroporphyrinogens by hydroxyl radicals: evidence for nonporphyrin products as potential inhibitors of uroporphyrinogen decarboxylase. Febs Lett 1988; 233:311-314
83. De Matteis F. Role of iron in the hydrogen peroxide-dependent oxidation of hexahydroporphyrins (porphyrinogens): a possible mechanism for the exacerbation by iron of hepatic uroporphyria. Mol Pharmacol 1988;33:463-469
84. Francis JE, Smith AG Polycyclic aromatic hydrocarbons cause hepatic porphyria in iron-loaded CS7 BL/10 mice: comparison of uroporphyrinogen decarboxylase inhibition with induction of alkoxyphenoxazone dealkylations Biochem Biophys Res Common 1987;146:13-20
85. Lambrecht RW, Sinclair PR, Gorman N, Sinclair JF. Uroporphyrinogen oxidation catalyzed by reconstituted cytochrome P450IA2. Arch Biochem Biophys 1992;254:504-510
86. Jacobs JM, Sinclair PR, Lambrecht RW, Sinclair JF. Effects of iron-EDTA on uroporphyrinogen oxidation by liver microsomes. Febs Lett 1989;250:349-352
87. Sinclair PR, Gorman N, Walton HS, et al. Ascorbic acid inhibition of cytochrome P3450-catalysed uroporphyrin accumulation. Arch Biochem Biophys 1993;304:464-470
88. Sinclair PR, Gorman N, Shedlovsky SJ, et al. Low plasma ascorbic acid concentrations in porphyria cutanea tarda. Hepatology 1996;24:581A
89. d SWR mice. Biochem Pharmacol 1996;52:1407-1413
90. Sesardic D, Pasanen M, Pelkonen O, Boobis AR. Differential expression and regulation of members of the cytochrome P450IA gene subfamily in human tissues. Carcinogenesis 1990; 11:1183-1188
91. th International Symposium on Microsomes and Drug Oxidation, Los Angeles, July 1996
92. Van Gelder W, Siersema PD, Voogd A, et al The effect of desferrioxamine on iron metabolism and lipid peroxidation in hepatocytes of C57BL/10 mice in experimental uroporphyria. Biochem Pharmacol 1993;46:221-228